Ondine Biomedical reported significant growth in a trading update on Wednesday, with revenues doubling to $1.2m in 2023, driven by expanded hospital deployments of ‘Steriwave’.
Ondine Biomedical Inc. NPV (CDI)
03 May 2024 17:23:02
Source: Sharecast
The AIM-traded company said it now served 24 hospitals, including strategic gains in the UK and Spain, and its first deployment in Australia.
It said discussions were underway for distribution partnerships to accelerate market penetration.
Ondine was also entering the ICU market to replace mupirocin, and finalising plans for a US phase three clinical trial.
Funding support was expected from existing shareholders, while discussions with Health Insight Capital for the clinical trial were ongoing.
At 1211 BST, shares in Ondine Biomedical were down 3.7% at 6.5p.
Reporting by Josh White for Sharecast.com.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested Personal Pension (SIPP), we've got an account to suit your needs..
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
